Patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) frequently relapse on imatinib with acquisition of BCR-ABL kinase domain (KD) mutations. To analyze the changes that second-generation tyrosine kinase inhibitors (TKIs) have brought in mutation frequency and type, a database review was undertaken of the results of all the BCR-ABL KD mutation analyses performed in the authors' laboratory from January 2004 to January 2013.
Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement / Soverini, S.; De Benedittis, C.; Papayannidis, C.; Paolini, S.; Venturi, C.; Iacobucci, I.; Luppi, M.; Bresciani, P.; Salvucci, M.; Russo, D.; Sica, S.; Orlandi, E.; Intermesoli, T.; Gozzini, A.; Bonifacio, M.; Rigolin, G.M.; Pane, F.; Baccarani, M.; Cavo, M.; Martinelli, G.. - In: CANCER. - ISSN 0008-543X. - STAMPA. - 120:7(2014), pp. 1002-1009. [10.1002/cncr.28522]
Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement
SOVERINI, SIMONA;DE BENEDITTIS, CATERINA;PAPAYANNIDIS, CRISTINA;PAOLINI, STEFANIA;Venturi, C.;BACCARANI, MICHELE;CAVO, MICHELE;MARTINELLI, GIOVANNI
2014
Abstract
Patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) frequently relapse on imatinib with acquisition of BCR-ABL kinase domain (KD) mutations. To analyze the changes that second-generation tyrosine kinase inhibitors (TKIs) have brought in mutation frequency and type, a database review was undertaken of the results of all the BCR-ABL KD mutation analyses performed in the authors' laboratory from January 2004 to January 2013.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
